Showing results (1-10 of 17) with videos related to
Sort By:
Pageof 2
Drug Discovery Today|October 21, 2015
Precision medicine in oncology drug development: a pharma perspectiveSimon J HollingsworthPublic Health Genomics|November 12, 2015
The Challenges of Precision Oncology Drug Development and ImplementationSimon J Hollingsworth, Andrew V BiankinThe Journal of Pathology|October 12, 2013
The impact of germline mutations on targeted therapySimon A Smith, Tim French, Simon J HollingsworthNature|October 16, 2015
Patient-centric trials for therapeutic development in precision oncologyAndrew V Biankin, Steven Piantadosi, Simon J HollingsworthJournal of the American Podiatric Medical Association|January 21, 2003
Use of a needleless injection system for digital ring block anesthesiaMichael Dialynas, Simon J Hollingsworth, David Cooper, et al.Pancreas|November 1, 2005
Advanced qRT-PCR technology allows detection of the cholecystokinin 1 receptor (CCK1R) expression in human pancreasJose Galindo, Neil Jones, Garth L Powell, et al.Journal of Surgical Oncology|November 22, 2005
Expression of angiogenic VEGF-A (soluble isoforms 121, 165) and lymphangiogenic VEGF-C in colorectal cancers with micro-satellite instabilitySimon J Hollingsworth, Elizabeth R Drye, Samson I H Tou, et al.Regulatory Peptides|June 20, 2006
Neuromedin U stimulates contraction of human long saphenous vein and gastrointestinal smooth muscle in vitroNeil A Jones, Magda F Morton, Clodagh E Prendergast, et al.Nature Reviews. Cancer|April 27, 2016
Defining actionable mutations for oncology therapeutic developmentT Hedley Carr, Robert McEwen, Brian Dougherty, et al.JCO Precision Oncology|September 14, 2020
Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in MET-Amplified Gastric CancerMelanie M Frigault, Aleksandra Markovets, Barrett Nuttall, et al.Pageof 2